Last reviewed · How we verify

Disorder of electrolytes — Treatment Landscape & Competitive Intelligence

Disorder of electrolytes (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Disorder of electrolytes, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Phoslo CALCIUM ACETATE Fresenius Medcl Care calcium acetate 1982-01-01
Calcium Gluceptate calcium glucoheptonate Abbott calcium glucoheptonate 1972-01-01
Plegisol In Plastic Container CALCIUM CHLORIDE Pfizer calcium chloride 1971-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Disorder of electrolytes
  2. Abbott · 1 drug in Disorder of electrolytes
  3. Fresenius Medcl Care · 1 drug in Disorder of electrolytes
  4. Pfizer · 1 drug in Disorder of electrolytes

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Disorder of electrolytes:

Cite this brief

Drug Landscape (2026). Disorder of electrolytes — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/disorder-of-electrolytes. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing